Non-Hodgkin Lymphoma

The FDA has granted a priority designation to a supplemental new drug application for ibrutinib for use in combination with obinutuzumab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the RELEVANCE trial in previously untreated patients with follicular lymphoma.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the use of CAR T-cell therapy in patients with DLBCL and the associated toxicities with each product, as well as other promising therapies in the paradigm.

Combining brentuximab vedotin with frontline chemotherapy led to a statistically significant improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma, according to topline results from the phase III ECHELON-2 trial.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory follicular lymphoma.

Cure rates in diffuse large B-cell lymphoma remain relatively unchanged, even following therapeutic additions to the armamentarium and an improved understanding of disease biology.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of bridging chemotherapy in patients receiving chimeric antigen receptor (CAR) T-cell therapy.

Philip Bierman, MD, discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that should be conducted.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with non–Hodgkin lymphoma (NHL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the construction of antibody-drug conjugates for the treatment of patients with lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Celeste Bello, MD, discusses the latest advances in the treatment of patients with follicular lymphoma.

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant, Moffitt Cancer Center, and an assistant professor of oncology at the University of South Florida, discusses unanswered questions with chimeric antigen receptor T-cell therapy.

David G. Maloney, MD, PhD, reviews the latest developments with chimeric antigen receptor T-cell therapy in patients with non-Hodgkin lymphoma.

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

The European Commission has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.

The FDA has approved ibrutinib in combination with rituximab for the treatment of patients with Waldenström macroglobulinemia.

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the treatment of Burkitt lymphoma in adult patients.

Ian W. Flinn, MD, PhD, discusses the latest developments with CAR T-cell therapies and other recent advances in the field of lymphoma.

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

The FDA has approved mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

David M. Kurtz, MD, PhD, discusses the clinical use of circulating tumor DNA in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.